Clinical Research Center, School of Medicine, Inha University, 7-206, 3-Ga, Shinheung-Dong, Jung-Gu, Incheon 400-711, Republic of Korea.
Cell Immunol. 2010;261(1):57-63. doi: 10.1016/j.cellimm.2009.11.001. Epub 2009 Nov 10.
Effects of mesenchymal stem cells (MSCs) on graft-versus-host disease (GVHD) have been actively investigated since the discovery of the immunomodulation property of MSCs about a decade ago. Human clonal MSCs (hcMSCs) were isolated from human bone marrow aspirate according to our newly established isolation protocol called subfractionation culturing method, and were evaluated for their efficacy on GVHD treatment, using a mouse MHC-matched B6-->BALB.B GVHD model system. Although the hcMSCs can suppress the allogeneic proliferation of human peripheral blood mononuclear cells in in vitro, the administration of the hcMSCs failed to reduce the GVHD-related mortality of the murine recipients. One of the reasons might be that murine cytokines such as IFN-gamma and TNF-alpha cannot activate the hcMSCs. Based on these results, we suggest that xenogeneic MSCs may not be used for the treatment of GVHD.
自十年前发现间充质干细胞（MSCs）具有免疫调节特性以来，人们一直在积极研究 MSCs 对移植物抗宿主病（GVHD）的影响。我们根据新建立的分离方案——亚分离培养法，从人骨髓抽吸物中分离出人克隆间充质干细胞（hcMSCs），并使用 MHC 匹配的 B6->BALB.B GVHD 模型系统评估其在 GVHD 治疗中的功效。尽管 hcMSCs 可以抑制体外同种异体人外周血单个核细胞的增殖，但 hcMSCs 的给药并不能降低小鼠受者与 GVHD 相关的死亡率。原因之一可能是 IFN-γ和 TNF-α等鼠细胞因子不能激活 hcMSCs。基于这些结果，我们建议异种间充质干细胞可能不适用于 GVHD 的治疗。
